Skip to main content

Rosetta, Collaborators Report on microRNAs in Epithelial-Mesenchymal Transition


Rosetta Genomics this week announced the publication of data demonstrating the involvement of certain microRNAs in epithelial-mesenchymal transition, or EMT, in cancers of unknown primary origin.

EMT is the acquisition of migratory, mesenchymal-like properties of epithelial cells, and is often associated with cancer metastasis.

According to the data, which appeared in Clinical & Translational Oncology, Rosetta and collaborators from the University of Ioannina studied the expression of 982 miRNAs in 68 cases of cancer of unknown primary origin.

They found that miR-203 and members of the miR-200 family were "consistently but non-significantly downregulated" in such cancers with the EMT phenotype.

"In view of the consistency of the observed levels of miR200 family expression by EMT status, more sensitive EMT-capturing technologies and larger [cancer of unknown primary origin] cohorts should be studied for further validation of these data," study co-author George Pentheroudakis said in a statement.

Rosetta currently markets an miRNA-based diagnostic for determining the source of cancers of unknown primary origin called the Rosetta Cancer Origin test.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.